Skip to main content
Allyson Ocean, MD, Oncology, New York, NY, New York-Presbyterian Hospital

AllysonJoyOceanMD

Oncology New York, NY

Associate Professor of Clinical Medicine, Weill Cornell Medical College

Overview of Dr. Ocean

Dr. Allyson Ocean is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. She received her medical degree from Tufts University School of Medicine and has been in practice 19 years. Dr. Ocean accepts several types of health insurance, listed below. She is one of 368 doctors at New York-Presbyterian Hospital and one of 115 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2001 - 2004
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1998 - 2001
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1998
  • George Mason University
    George Mason UniversityNo Degree, Pre-medical coursework, 1993 - 1994
  • Tufts University
    Tufts UniversityBA, International Relations, Cum Laude, 1989 - 1993
  • Institute of European Studies
    Institute of European StudiesNo Degree, 1991 - 1992

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1999 - 2024

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Anne Moore, M.D. Clinical Scholar Award in Gastrointestinal Oncology 2010
  • Grant Award Recipient Advanced Research Foundation, 2009
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase II trial of bortezomib alone or in combinationwith irinotecan in patients with adenocarcinomaof the gastroesophageal junction or stomach  
    Allyson J. Ocean, Paul Christos, Joseph A. Sparano, Manish A. Shah, Rhonda K. Yantiss, Jonathan Cheng , Juan Lin, Michael Papetti, Dan Matulich, Felice Schnoll-Sussman..., Invest New Drugs, 1/1/2014
  • Fractionated Radioimmunotherapy (RAIT) With 90Y-Clivatuzumab Tetraxetan (90Y-hPAM4) And Low-dose Gemcitabine Is Active In Advanced Pancreatic Cancer: A Phase I trial  
    Allyson J. Ocean, MD; Kenneth L. Pennington, MD; Michael J. Guarino, MD; Arif Sheikh, MD; Tanios Bekaii-Saab, MD; Aldo N. Serafini, MD; Daniel Lee, MD; Max W. Sung, MD..., Cancer, 1/8/2012
  • Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach  
    Carlson K, Ocean AJ, Clinical Breast Cancer, 1/1/2011
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Phase I/II trial of intraperitoneal implantation of agarose-agarosemacrobeads (MB) containing mouse renal adenocarcinoma cells (RENCA) in patients (pts) with advanced ...
    Allyson J. Ocean, Tapan Parikh, Nathaniel Berman, Juliet Escalon, Manish A. Shah, Zoe Andrada, Eugene Akahoho, Janice M. Pogoda, George B. Stoms, Verula B Escobia, Jos..., J Clin Oncol, 1/1/2013
  • Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.
    Naveed Hassan Akhtar, Beerinder Singh, Allyson J. Ocean, Irene Karpenko, Himisha Beltran, Elizabeta C. Popa, David M. Nanus, Manish A. Shah, Scott T. Tagawa, J Clin Oncol, 1/1/2013
  • The incidence and impact of poor nutrition in gastrointestinal malignancies.
    Douglas Eric Guggenheim, Allyson J. Ocean, Elizabeta C. Popa, Amanda R Magli, Irene Karpenko, Paul J. Christos, Veronica A. Rosales, Erika Ocampo Florendo, Joseph T. R..., J Clin Oncol, 1/1/2013
  • Join now to see all

Lectures

  • “Current Standard and Experimental Treatments in Pancreatic Cancer: Chemotherapy and Targeted Therapies.” 
    1/19/2011
  • “Early Stage Colorectal Cancer: Reducing Risk of Recurrence.” 
    New York Presbyterian Hospital-Columbia - 1/13/2011
  • “ClivatuzumabTetraxetan for the Therapy of Patients with Pancreatic Cancer.” 
    New York City, NY - 1/15/2010
  • Join now to see all

Other

Press Mentions

  • No Longer a Death Sentence: New Treatments for Pancreatic Cancer Offer Patients Hope
    No Longer a Death Sentence: New Treatments for Pancreatic Cancer Offer Patients HopeMay 20th, 2023
  • Study of SM-88 Shows Promising Results in Advanced Pancreatic Cancer
    Study of SM-88 Shows Promising Results in Advanced Pancreatic CancerAugust 4th, 2019
  • TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer
    TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic CancerJuly 8th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment